Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuardâ€¯and Oncotype DX, along with solutions likeâ€¯Cancerguardâ€¯forâ€¯blood-based analysis of molecular information across multiple cancersâ€¯andâ€¯Oncodetectâ€¯for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.

Employees

7,150

Sector

Biotechnology & Medical Research

More about the company

Analysis / Opinion

Exact Sciences CEO on Launch of Multi-Cancer Blood Test

September 15, 2025 at 11:32 am

More analyses

Market Cap	20.03B 103B 17.15B 16.05B 14.69B 27.57B 1,916B 27.94B 190B 73.95B 963B 75.2B 73.56B 3,184B	P/E 2024	-10.1x	P/E 2025	-92.2x
Enterprise Value	21.6B 111B 18.5B 17.31B 15.84B 29.74B 2,066B 30.13B 205B 79.75B 1,038B 81.09B 79.33B 3,433B	EV / Sales 2024	4.4x	EV / Sales 2025	6.42x
Free-Float	98.24%	Yield 2024 *	-	Yield 2025	-

03-24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index	CI
03-24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index	CI
03-24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P TMI Index	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell Small Cap Comp Value Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell Small Cap Comp Growth Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell Midcap Value Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 1000 Growth Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 3000E Value Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 3000E Growth Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 3000 Value Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 3000 Growth Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 2500 Value Benchmark	CI
03-23	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from Russell 2500 Growth Benchmark	CI

01-20	Mizuho Downgrades Exact Sciences to Neutral From Outperform, Adjusts Price Target to $105 From $85	MT
01-20	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
12-01	Stifel Downgrades Exact Sciences to Hold From Buy, Adjusts Price Target to $105 From $80	MT
11-25	Canaccord Genuity Downgrades Exact Sciences to Hold From Buy, Adjusts PT to $105 From $85	MT
11-25	TD Cowen Downgrades Exact Sciences to Hold From Buy, Adjusts PT to $105 From $90	MT

03-17	Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026	BU
03-04	Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year	BU
02-20	Exact Sciences Stockholders Approve Acquisition by Abbott	BU
02-13	Exact Sciences: Q4 Earnings Snapshot	AQ
02-13	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results	BU

03-23	Les marchés américains reprennent des couleurs après la décision inattendue de Trump
03-23	Exact Sciences devient une filiale à 100 % d'Abbott
01-31	El próximo presidente de la Fed: ¿reformista, realista o simple ejecutor?
11-25	Wall Street coincée dans sa mue permanente
11-21	Wall Street : Même l'excellence ne suffit pas

Exact Sciences Corporation Stock Sao Paulo

Stocks

E2XA34

BRE2XABDR009

Biotechnology & Medical Research

Valuation: Exact Sciences Corporation

Chart: Exact Sciences Corporation

Latest news : Exact Sciences Corporation

Last Transcript: Exact Sciences Corporation

Analysts' recommendations: Exact Sciences Corporation

Press Releases: Exact Sciences Corporation

News in other languages: Exact Sciences Corporation

Quotes and Performance

Bio Diagnostics & Testing

Financials

Company Profile

Analysis / Opinion

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT SCIENCES CORPORATION	+1.12%	+0.50%	-	-	20.03B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.16%	+5.05%	+99.92%	+299.85%	4.15B
IOVANCE BIOTHERAPEUTICS, INC.	-7.79%	+18.77%	+208.18%	+31.38%	3.76B
VERACYTE, INC.	+1.24%	+2.57%	+36.48%	+61.24%	3.4B
CAREDX, INC.	+3.45%	+7.26%	+274.79%	+454.28%	2.51B
BGI GENOMICS CO., LTD.	-3.61%	+3.84%	-21.05%	-19.77%	2.41B
FREENOME, INC.	-0.88%	+16.87%	+27.81%	-	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+4.22%	+51.58%	+252.65%	-18.26%	1.29B
SEEGENE, INC.	-2.40%	-5.13%	+16.63%	+41.86%	1B
HANGZHOU ALLTEST BIOTECH CO., LTD.	-2.72%	-2.82%	-36.30%	+1.72%	552M
Average	-0.52%	+11.21%	+95.46%	+106.54%	2.28B
Weighted average by Cap.	+0.16%	+10.61%	+113.05%	+140.74%

	2024	2025
Net sales	2.76B 14.24B 2.36B 2.21B 2.02B 3.8B 264B 3.85B 26.13B 10.19B 133B 10.36B 10.13B 439B	3.25B 16.76B 2.78B 2.6B 2.38B 4.47B 311B 4.53B 30.75B 11.99B 156B 12.19B 11.93B 516B
Net income	-1.03B -5.31B -881M -825M -755M -1.42B -98.44B -1.44B -9.74B -3.8B -49.45B -3.86B -3.78B -164B	-208M -1.07B -178M -167M -153M -286M -19.9B -290M -1.97B -768M -9.99B -781M -764M -33.06B
Net Debt	1.74B 8.97B 1.49B 1.39B 1.27B 2.39B 166B 2.42B 16.46B 6.42B 83.52B 6.52B 6.38B 276B	1.57B 8.1B 1.34B 1.26B 1.15B 2.16B 150B 2.19B 14.87B 5.8B 75.47B 5.9B 5.77B 250B